Cargando…

Usefulness of plasma matrix metalloproteinase-9 levels in prediction of in-hospital mortality in patients who received emergent percutaneous coronary artery intervention following myocardial infarction

The aim of the present study was to investigate the predictive value of the plasma matrix metalloproteinase-9 (MMP-9) level at admission for in-hospital mortality in patients who received emergency percutaneous coronary intervention (PCI) following AMI. A single blood sample was collected at admissi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Jia-Jun, Zhao, Qian, Qu, Hui-Juan, Li, Xiao-Mei, Chen, Qing-Jie, Liu, Fen, Chen, Bang-Dang, Yang, Yi-Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739681/ https://www.ncbi.nlm.nih.gov/pubmed/29285294 http://dx.doi.org/10.18632/oncotarget.22401

Ejemplares similares

Matrix metalloproteinases in coronary artery disease and myocardial infarction
por: Bräuninger, Hanna, et al.
Publicado: (2023)

Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction
por: Guzel, Savas, et al.
Publicado: (2013)

Erratum: Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in myocardial infarction
por: Guzel, Savas, et al.
Publicado: (2013)

Genetic Polymorphism of Matrix Metalloproteinase-9 and Susceptibility to Myocardial Infarction: A Meta-Analysis
por: Feng, Beili, et al.
Publicado: (2022)

Myocardial Injury Promotes Matrix Metalloproteinase-9 Activity in the Renal Cortex in Preclinical Models of Acute Myocardial Infarction
por: Qiao, Xiaoying, et al.
Publicado: (2021)

Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women
por: Jefferis, Barbara J., et al.
Publicado: (2010)

Prognostic Analysis for Cardiogenic Shock in Patients with Acute Myocardial Infarction Receiving Percutaneous Coronary Intervention
por: Lin, Mao-Jen, et al.
Publicado: (2017)

Association of Matrix Metalloproteinase 9 C-1562T Polymorphism with Genetic Susceptibility to Myocardial Infarction: A Meta-Analysis
por: Juan, Zhang, et al.
Publicado: (2015)

Matrix metalloproteinases and their gene polymorphism in young ST-segment elevation myocardial infarction
por: Basia, Deepak, et al.
Publicado: (2022)

Huoxue Rongluo Tablet reduces matrix metalloproteinase-9 expression in infarcted brain tissue
por: Zhou, Desheng, et al.
Publicado: (2013)

Matrix Metalloproteinase-9 Relationship With Infarct Growth and Hemorrhagic Transformation in the Era of Thrombectomy
por: Mechtouff, Laura, et al.
Publicado: (2020)

Association between Serum Vitamin D Concentration Status and Matrix Metalloproteinase-9 in Patients Undergoing Elective Percutaneous Coronary Intervention
por: Foroughinia, Farzaneh, et al.
Publicado: (2020)

Association Between High Serum Matrix Metalloproteinase-9 and MMP-9 (-1562C>T) Polymorphism in Patients With ST-Elevation Acute Myocardial Infarction
por: Setianto, Budi Y., et al.
Publicado: (2012)

Rhubarb Antagonizes Matrix Metalloproteinase-9-induced Vascular Endothelial Permeability
por: Cui, Yun-Liang, et al.
Publicado: (2016)

Comparing efficacy of receiving different dosages of eptifibatide in bleeding after percutaneous coronary intervention in patients with myocardial infarction
por: Shemirani, Hasan, et al.
Publicado: (2019)

Outcomes of Elderly Patients With Acute Myocardial Infarction and Heart Failure Who Undergo Percutaneous Coronary Intervention
por: Nishihira, Kensaku, et al.
Publicado: (2022)

NT-proBNP and Major Adverse Cardiovascular Events in Patients with ST-Segment Elevation Myocardial Infarction Who Received Primary Percutaneous Coronary Intervention: A Prospective Cohort Study
por: Qin, Zuoan, et al.
Publicado: (2021)

Systemic Immune-Inflammatory Index Predicts Clinical Outcomes for Elderly Patients with Acute Myocardial Infarction Receiving Percutaneous Coronary Intervention
por: Huang, Jiabao, et al.
Publicado: (2019)

Risk assessment model for predicting ventricular tachycardia or ventricular fibrillation in ST-segment elevation myocardial infarction patients who received primary percutaneous coronary intervention
por: Huang, Jiabing, et al.
Publicado: (2019)

Plasma Matrix Metalloproteinase-9 and Tissue Inhibitor of Matrix Metalloproteinase-1 as Prognostic Biomarkers in Critically Ill Patients
por: Duda, Izabela, et al.
Publicado: (2020)

In vitro validation of the tear matrix metalloproteinase 9 in-situ immunoassay
por: Bang, Seung Pil, et al.
Publicado: (2020)

A case report of acute myocardial infarction with extremely severe thrombocytopenia after percutaneous coronary intervention
por: Chen, Shuai, et al.
Publicado: (2023)

Percutaneous coronary intervention for acute myocardial infarction with mitral regurgitation
por: Tu, Yan, et al.
Publicado: (2016)

Serum Apelin Level Predicts the Major Adverse Cardiac Events in Patients With ST Elevation Myocardial Infarction Receiving Percutaneous Coronary Intervention
por: Liu, Hai-Tao, et al.
Publicado: (2015)

Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in early focal cerebral infarction following urokinase thrombolysis in rats☆
por: Song, Yuqiang, et al.
Publicado: (2012)

Association Between Lipoprotein(a) and Peri-procedural Myocardial Infarction in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention
por: Liu, Yupeng, et al.
Publicado: (2021)

Association of thrombocytopenia and infection in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention
por: Wang, Litao, et al.
Publicado: (2021)

Prognostic value of tissue inhibitor of metalloproteinase-matrix metalloproteinase biomarkers at 30 days in patients with acute myocardial infarction without reperfusion therapy
por: Pang, Hui-Fang, et al.
Publicado: (2021)

Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer
por: Tanioka, Y, et al.
Publicado: (2003)

Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis Patients
por: Trentini, Alessandro, et al.
Publicado: (2016)

Matrix Metalloproteinase-1 and Matrix Metalloproteinase-9 in the Aqueous Humor of Diabetic Macular Edema Patients
por: Kwon, Jin-woo, et al.
Publicado: (2016)

Comparison of primary coronary percutaneous coronary intervention between Diabetic Men and Women with acute myocardial infarction
por: Liu, Heng-Liang, et al.
Publicado: (2015)

Serum calcium, albumin, globulin and matrix metalloproteinase-9 levels in acute cerebral infarction patients
por: Zhong, Ting-Ting, et al.
Publicado: (2021)

Matrix metalloproteinase-9 gene polymorphisms in nasal polyposis
por: Wang, Ling-Feng, et al.
Publicado: (2010)

A new cooperative approach for ST-elevation myocardial infarction patients to receive timely and effective percutaneous coronary reperfusion in China
por: Yan, Jin-Chuan, et al.
Publicado: (2016)

Selection of percutaneous coronary intervention in elderly patients with acute myocardial infarction in tertiary hospital
por: Chen, Liwei, et al.
Publicado: (2019)

Expression of matrix metalloproteinases-12 in ST-segment elevation myocardial infarction: A case–control study
por: Wang, Jing, et al.
Publicado: (2017)

Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson’s disease
por: Liu, Chuan Ze, et al.
Publicado: (2022)

Imbalance of matrix metalloproteinase-9 and matrix metalloproteinase tissue inhibitor-1 may contribute to hemorrhage in cerebellar arteriovenous malformations☆
por: Di, Fei, et al.
Publicado: (2012)

Overcrowding is associated with delays in percutaneous coronary intervention for acute myocardial infarction
por: Kulstad, Erik B., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_p21f1q7e7rpo064ftfmsc1js2k